Micafungin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Micafungin |
| DrugBank ID | DB01141 |
| Brand Names (EU) | Mycamine |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.03% |
Approved Indication (EMA)
Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate; prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days. Children (including neonates) and adolescents < 16 years of age
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | urinary tract infection (disease) | 99.03% | DL |
| 2 | gonococcal urethritis | 98.98% | DL |
| 3 | Ureaplasma urethritis | 98.98% | DL |
| 4 | uterine inflammatory disease | 98.70% | DL |
| 5 | xanthogranulomatous pyelonephritis | 98.67% | DL |
| 6 | malignant pleural mesothelioma | 98.09% | DL |
| 7 | malignant epithelioid mesothelioma | 97.23% | DL |
| 8 | malignant visceral pleura tumor | 97.08% | DL |
| 9 | sarcomatoid mesothelioma | 97.08% | DL |
| 10 | urogenital tuberculosis | 96.79% | DL |
| 11 | impetigo | 94.77% | DL |
| 12 | cysticercosis | 93.38% | DL |
| 13 | hordeolum | 93.37% | DL |
| 14 | staphylococcal scalded skin syndrome | 92.63% | DL |
| 15 | coenurosis | 92.61% | DL |
| 16 | pleural neoplasm | 92.00% | DL |
| 17 | candidemia | 90.52% | DL |
| 18 | bullous impetigo | 90.35% | DL |
| 19 | Clostridium infectious disease | 88.78% | DL |
| 20 | herpes zoster | 88.03% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.